CA3089970A1 - Therapeutic compounds and compositions - Google Patents
Therapeutic compounds and compositions Download PDFInfo
- Publication number
- CA3089970A1 CA3089970A1 CA3089970A CA3089970A CA3089970A1 CA 3089970 A1 CA3089970 A1 CA 3089970A1 CA 3089970 A CA3089970 A CA 3089970A CA 3089970 A CA3089970 A CA 3089970A CA 3089970 A1 CA3089970 A1 CA 3089970A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- compound
- composition
- pharmaceutically acceptable
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627435P | 2018-02-07 | 2018-02-07 | |
| US62/627,435 | 2018-02-07 | ||
| PCT/US2019/016503 WO2019156929A1 (en) | 2018-02-07 | 2019-02-04 | Therapeutic compounds and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089970A1 true CA3089970A1 (en) | 2019-08-15 |
Family
ID=67548561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089970A Pending CA3089970A1 (en) | 2018-02-07 | 2019-02-04 | Therapeutic compounds and compositions |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11691962B2 (https=) |
| EP (1) | EP3749662A4 (https=) |
| JP (2) | JP7397797B2 (https=) |
| KR (1) | KR20200118088A (https=) |
| CN (1) | CN111902404A (https=) |
| AU (1) | AU2019217366B2 (https=) |
| BR (1) | BR112020016123A2 (https=) |
| CA (1) | CA3089970A1 (https=) |
| IL (2) | IL276563B1 (https=) |
| WO (1) | WO2019156929A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| EP3749662A4 (en) | 2018-02-07 | 2021-07-14 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4595532A (en) | 1983-02-02 | 1986-06-17 | University Of Notre Dame Du Lac | N-(substituted-methyl)-azetidin-2-ones |
| EP1051431A1 (de) | 1998-01-26 | 2000-11-15 | Basf Aktiengesellschaft | Thrombininhibitoren |
| US6335324B1 (en) | 1998-06-25 | 2002-01-01 | Bristol-Myers Squibb Co. | Beta lactam compounds and their use as inhibitors of tryptase |
| AU752320B2 (en) | 1998-06-25 | 2002-09-12 | Bristol-Myers Squibb Company | Amidino and guanidino azetidinone tryptase inhibitors |
| AU4654199A (en) | 1998-07-23 | 2000-02-14 | Shionogi & Co., Ltd. | Monocyclic beta-lactam compounds and chymase inhibitors containing the same |
| US20070032466A1 (en) | 2003-08-22 | 2007-02-08 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| CA2648522A1 (en) * | 2005-04-04 | 2006-10-12 | Daiamed, Inc. | Substituted azetidinones |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| ES2674745T3 (es) | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| KR101937514B1 (ko) | 2011-10-14 | 2019-01-10 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물 |
| US9730921B2 (en) | 2012-03-27 | 2017-08-15 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| US20190315711A1 (en) | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3749662A4 (en) | 2018-02-07 | 2021-07-14 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
| KR20210084581A (ko) | 2018-10-30 | 2021-07-07 | 엑시테라 파마슈티컬스 인코퍼레이티드 | 치료 화합물 및 조성물 |
| WO2020092592A1 (en) | 2018-10-30 | 2020-05-07 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP3917910A4 (en) | 2019-01-29 | 2022-11-09 | Exithera Pharmaceuticals Inc. | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
-
2019
- 2019-02-04 EP EP19751349.2A patent/EP3749662A4/en not_active Withdrawn
- 2019-02-04 BR BR112020016123-3A patent/BR112020016123A2/pt unknown
- 2019-02-04 CA CA3089970A patent/CA3089970A1/en active Pending
- 2019-02-04 AU AU2019217366A patent/AU2019217366B2/en active Active
- 2019-02-04 JP JP2020542552A patent/JP7397797B2/ja active Active
- 2019-02-04 CN CN201980021810.6A patent/CN111902404A/zh active Pending
- 2019-02-04 WO PCT/US2019/016503 patent/WO2019156929A1/en not_active Ceased
- 2019-02-04 KR KR1020207024907A patent/KR20200118088A/ko active Pending
-
2020
- 2020-08-06 US US16/986,658 patent/US11691962B2/en active Active
- 2020-08-06 IL IL276563A patent/IL276563B1/en unknown
-
2023
- 2023-02-17 US US18/170,858 patent/US12152014B2/en active Active
- 2023-12-01 JP JP2023203652A patent/JP2024023490A/ja active Pending
-
2025
- 2025-12-21 IL IL325484A patent/IL325484A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024023490A (ja) | 2024-02-21 |
| CN111902404A (zh) | 2020-11-06 |
| EP3749662A4 (en) | 2021-07-14 |
| KR20200118088A (ko) | 2020-10-14 |
| US12152014B2 (en) | 2024-11-26 |
| AU2019217366B2 (en) | 2024-07-11 |
| US11691962B2 (en) | 2023-07-04 |
| EP3749662A1 (en) | 2020-12-16 |
| AU2019217366A1 (en) | 2020-08-20 |
| BR112020016123A2 (pt) | 2021-02-23 |
| US20240059670A1 (en) | 2024-02-22 |
| IL325484A (en) | 2026-02-01 |
| JP2021512894A (ja) | 2021-05-20 |
| WO2019156929A1 (en) | 2019-08-15 |
| JP7397797B2 (ja) | 2023-12-13 |
| US20210188812A1 (en) | 2021-06-24 |
| RU2020129237A (ru) | 2022-03-09 |
| IL276563A (en) | 2020-09-30 |
| IL276563B1 (en) | 2026-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12084414B2 (en) | Therapeutic compounds and compositions | |
| JP2013121919A (ja) | 血漿カリクレイン阻害剤 | |
| US20210261524A1 (en) | Therapeutic compounds and compositions | |
| WO2018118705A1 (en) | Therapeutic compounds and compositions | |
| US12152014B2 (en) | Therapeutic compounds and compositions | |
| US20210253550A1 (en) | Therapeutic compounds and compositions | |
| RU2817800C2 (ru) | Терапевтические соединения и композиции | |
| JP2023518262A (ja) | Ｐｈｄ阻害剤化合物、組成物、及び使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220912 |